MAY 20·Simply Wall Street→
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.
MAY 20·MarketBeat▲
North Dakota State Investment Board Buys Shares of 19,728 Edwards Lifesciences Corporation $EW
The North Dakota State Investment Board has acquired a new stake of 19,728 shares in Edwards Lifesciences Corporation, valued at approximately $1.68 million, during the fourth quarter. This move comes as Edwards Lifesciences reported strong quarterly results, exceeding analyst expectations with $0.78 EPS and $1.65 billion in revenue, driven by 16.7% year-over-year revenue growth. Analysts maintain a "Moderate Buy" consensus for the stock with a target price of $95.65, despite recent insider share sales.
